BioLife Solutions (NASDAQ:BLFS) released its earnings results on Thursday. The medical equipment provider reported $0.04 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.04, Morningstar.com reports. The company had revenue of $5.46 million during the quarter, compared to analysts’ expectations of $5.47 million. BioLife Solutions had a return on equity of 8.63% and a net margin of 10.42%. BioLife Solutions updated its FY 2019 guidance to EPS.
BLFS stock traded up $1.03 on Friday, reaching $18.72. 152,690 shares of the company traded hands, compared to its average volume of 155,449. BioLife Solutions has a one year low of $4.85 and a one year high of $26.35. The firm has a market cap of $327.27 million, a PE ratio of -89.17 and a beta of 1.65.
BLFS has been the subject of a number of research analyst reports. ValuEngine upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, January 31st. Janney Montgomery Scott upgraded BioLife Solutions to a “buy” rating and set a $5.00 target price for the company in a research note on Thursday, December 20th. BidaskClub upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Finally, Zacks Investment Research cut BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $17.75.
Hedge funds have recently bought and sold shares of the stock. Canton Hathaway LLC bought a new stake in shares of BioLife Solutions in the 4th quarter worth $66,000. GSA Capital Partners LLP bought a new stake in shares of BioLife Solutions in the 3rd quarter worth $200,000. Northern Trust Corp increased its holdings in shares of BioLife Solutions by 24.4% in the 2nd quarter. Northern Trust Corp now owns 16,304 shares of the medical equipment provider’s stock worth $186,000 after purchasing an additional 3,200 shares in the last quarter. Monashee Investment Management LLC bought a new stake in shares of BioLife Solutions in the 3rd quarter worth $337,000. Finally, Bank of Montreal Can increased its holdings in shares of BioLife Solutions by 91.6% in the 3rd quarter. Bank of Montreal Can now owns 19,286 shares of the medical equipment provider’s stock worth $338,000 after purchasing an additional 9,222 shares in the last quarter. 40.67% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “BioLife Solutions (BLFS) Posts Earnings Results, Hits Estimates” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/4223420/biolife-solutions-blfs-posts-earnings-results-hits-estimates.html.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.
Featured Article: Fiduciary
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.